echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Immunity: B7H3/B7H4 is expected to become a new target for colorectal cancer immunotherapy

    Immunity: B7H3/B7H4 is expected to become a new target for colorectal cancer immunotherapy

    • Last Update: 2022-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Colorectal cancer (CRC) is one of the most common cancers


    colorectal cancer immunity

    On March 31, researchers at the Technical University of Dresden published their latest findings in Immunity, in which they identified the proteins B7H3 and B7H4, promising targets for new immunotherapies against colorectal cancer, and highlighted gut bacteria Central role in the development of colorectal cancer


     

    The research team has previously demonstrated that bacterial sensing of intestinal tumor cells promotes tumor growth through intracellular activation of calcineurin, as well as calcineurin-dependent activation of activated T cell nuclear transcription factor (NFAT)


    In mouse experiments, antibody-mediated blockade or genetic deletion of members of this pathway inhibited tumor development and promoted regression of metastatic colorectal cancers, demonstrating that perturbation of members of this pathway activates CD8 + T cell-dependent Antitumor immunity and durable disease control


    + + Tumor immunity

    Specifically, myeloid tumor-infiltrating cells exhibit microbiota-dependent activation of calcineurin and NFAT, which orchestrate an immunosuppressive crosstalk network in microsatellite-stabilized colorectal cancer that is dependent on myeloid IL-6 and correlated with STAT3-dependent expression of colorectal cancer cell co-repressors B7H3 and B7H4, which in turn inhibited CD8 + T cell responses


    + + Source: Immunity

    B7H3 and B7H4 are two B7 family members that interact with unknown receptors expressed by T cells


    + +

    The study also showed that the expression of B7H3 and B7H4 was almost exclusively derived from epithelial tumor cells rather than tumor-infiltrating immune cells (Panel C, lower panel, which was confirmed by immunohistochemistry (Panel B, lower panel)


     

    Source: Immunity

    Source: Immunity

     

    A series of experiments further verified that B7H3 and B7H4 indeed function as checkpoint proteins


    In addition, the research team pointed out that breaking the intestinal barrier is a key factor in promoting colorectal cancer to improve its ability to resist immune cells


    Corresponding author Professor Sebastian Zeissig said: "Our findings provide a new link between the microbiota and tumor growth in colorectal cancer


    Collectively, this study uncovers a pathway that inhibits microsatellite-stabilized CD8 +


    + +

    Prof Zeissig said: "Our analysis of human samples showed that B7H3 and B7H4 are also present in human colorectal cancer cells and that their presence is associated with poorer prognosis in patients with colorectal cancer


    Original source:

    Original source:

    Kenneth Peuker et al.




    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.